Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) with TP53 mutation generally have poor prognosis, almost irrespective of the treatment administered, including after allogeneic Hematopoietic Stem Cell Transplantation (aHSCT). Here, TP53 is linked to acute myeloid leukemia.